Dr. Peter G. Milner Fellowship for Biomedical Innovation 2024

Published on

Dr Peter Milner (3rd in from left) with Christian Flynn & Stephen McKeever; Tom Walley; Paul May and Sam Latham

Two Dr Peter G. Milner Fellowships for Biomedical Innovation have been awarded to Cian O'Halloran and Andrew Bonsu, who impressed the judging panel with their combination of medical and business skills.

These prestigious Fellowships enables foundation doctors and core medical trainees to gain experience in the USA's medical and biopharmaceutical healthcare companies.

The fellowship has been made possible thanks to the generosity of Dr Peter Milner, a distinguished physician and alumnus of the University of Liverpool (BSc Biochemistry 1978, MBChB Medicine 1980). California-based Dr Milner is the Chairman and Chief Executive Officer of Renexxion, and a successful cardiologist and entrepreneur with extensive experience in drug development and clinical trial design in cardiovascular indications, with an emphasis on imaging.

Dr Peter Milner said: “Liverpool Medical School is a fantastic resource and having realized the pool of talent that is available amongst well-trained doctors who have capacity for business, I have granted multiple fellowships over the last few years. My colleagues and I in my businesses in the US and Ireland have been very impressed with the medical knowledge of these fellows and their ability to apply it to pharmaceutical research, development, and commercialization. They have demonstrated how capable they are in picking up new business and financial skills that are important in advancing products through clinical trials in coordination with global regulatory agencies to gain approval, negotiate the label, and predict revenue."

Last year fellow, Stephen McKeever shared how the fellowship helped shape his career:

Stephen McKeever said:” The Peter Milner Fellowship has provided its fellows an opportunity to build upon our medical foundation and opened up a range of experiences within the pharmaceutical industry, which has included clinical trial design, regulatory affairs, and fundraising. The fellowship has evolved into a role that has enhanced my clinical and academic work, as well as career opportunities outside of UK medicine. I look forward to welcoming the new fellows into the group and sharing our experiences to develop their understanding of drug development and aid in their career progression.”

To find out more about the Fellowship and how it supports doctors in their future careers visit our webpage.